Potential of Ginsenoside Rg1 to Treat Aplastic Anemia Mitogen Activated Protein Kinase Pathway in Cyclophosphamide-induced Myelosuppression Mouse Model

Overview

Journal World J Stem Cells

Publisher Baishideng Publishing Group

Date 2024 Dec 2

PMID 39619872

Authors

See-Hyoung Park

Affiliations

Soon will be listed here.

Abstract

Aplastic anemia (AA) is a rare but serious condition in which the bone marrow fails to produce sufficient new blood cells, leading to fatigue, increased susceptibility to infection, and uncontrolled bleeding. In this editorial, we review and comment on an article by Wang published in 2024. This study aimed to evaluate the potential therapeutic benefits of ginsenoside Rg1 in AA, focusing on its protective effects and uncovering the underlying mechanisms. Cyclophosphamide (CTX) administration caused substantial damage to the structural integrity of the bone marrow and decreased the number of hematopoietic stem cells, thereby establishing an AA model. Compared with the AA group, ginsenoside Rg1 alleviated the effects of CTX by reducing apoptosis and inflammatory factors. Mechanistically, treatment with ginsenoside Rg1 significantly mitigated myelosuppression in mice by inhibiting the mitogen activated protein kinase signaling pathway. Thus, this study indicates that ginsenoside Rg1 could be effective in treating AA by reducing myelosuppression, primarily through its influence on the mitogen activated protein kinase signaling pathway. We expect that our review and comments will provide valuable insights for the scientific community related to this research and enhance the overall clarity of this article.

References

Miano M, Dufour C . The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015; 101(6):527-35. DOI: 10.1007/s12185-015-1787-z. View

Pan P, Chen C, Hong J, Gu Y . Autoimmune pathogenesis, immunosuppressive therapy and pharmacological mechanism in aplastic anemia. Int Immunopharmacol. 2023; 117:110036. DOI: 10.1016/j.intimp.2023.110036. View

Gamper C, Takemoto C, Chen A, Symons H, Loeb D, Casella J . High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. J Pediatr Hematol Oncol. 2016; 38(8):627-635. PMC: 5074865. DOI: 10.1097/MPH.0000000000000647. View

Jadon N, Shanthalingam S, Tew G, Minter L . PRMT5 regulates epigenetic changes in suppressive Th1-like iTregs in response to IL-12 treatment. Front Immunol. 2024; 14:1292049. PMC: 10800960. DOI: 10.3389/fimmu.2023.1292049. View

Li B, Guo L, Zhang Y, Xiao Y, Wu M, Zhou L . Molecular alterations in the TCR signaling pathway in patients with aplastic anemia. J Hematol Oncol. 2016; 9:32. PMC: 4818392. DOI: 10.1186/s13045-016-0261-6. View

Kuang Y, Zhu Y, Gao R, Hu J, Jiang Z, Huang L . Clinical study of pai-neng-da capsule in the treatment of chronic aplastic anemia. Chin J Integr Med. 2015; 22(2):124-9. DOI: 10.1007/s11655-015-2158-6. View

Ni R, Fan L, Zhang L, Song Y, Wang H, Wang A . A mouse model of irradiation and spleen-thymus lymphocyte infusion induced aplastic anemia. Hematology. 2022; 27(1):932-945. DOI: 10.1080/16078454.2022.2113356. View

Velasco Lezama R, Barrera Escorcia E, Munoz Torres A, Tapia Aguilar R, Gonzalez Ramirez C, Garcia Lorenzana M . A model for the induction of aplastic anemia by subcutaneous administration of benzene in mice. Toxicology. 2001; 162(3):179-91. DOI: 10.1016/s0300-483x(01)00371-7. View

Liu T, Pan Y, Ye M, Sun Q, Ding X, Xu M . Experience of life quality from patients with aplastic anemia: a descriptive qualitative study. Orphanet J Rare Dis. 2023; 18(1):393. PMC: 10740222. DOI: 10.1186/s13023-023-02993-y. View

10.

Solimando A, Palumbo C, Pragnell M, Bittrich M, Argentiero A, Krebs M . Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow. Int J Mol Sci. 2022; 23(19). PMC: 9569739. DOI: 10.3390/ijms231911765. View

11.

Wang J, Du M, Zheng Y . Effect of ginsenoside Rg1 on hematopoietic stem cells in treating aplastic anemia in mice MAPK pathway. World J Stem Cells. 2024; 16(5):591-603. PMC: 11135254. DOI: 10.4252/wjsc.v16.i5.591. View

12.

Li B, Liu S, Niu Y, Fang S, Wu X, Yu Z . Altered expression of the TCR signaling related genes CD3 and FcεRIγ in patients with aplastic anemia. J Hematol Oncol. 2012; 5:6. PMC: 3359239. DOI: 10.1186/1756-8722-5-6. View

13.

Urbanowicz I, Nahaczewska W, Celuch B . Narrative review of aplastic anemia-the importance of supportive treatment. Ann Palliat Med. 2020; 10(1):694-699. DOI: 10.21037/apm-20-1957. View

14.

Young N . Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013; 2013:76-81. PMC: 6610029. DOI: 10.1182/asheducation-2013.1.76. View

15.

Deng S, Zeng Y, Xiang J, Lin S, Shen J . Icariin protects bone marrow mesenchymal stem cells in aplastic anemia by targeting MAPK pathway. Mol Biol Rep. 2022; 49(9):8317-8324. DOI: 10.1007/s11033-022-07645-1. View

16.

Cao H, Wei W, Xu R, Cui X . Ginsenoside Rg1 can restore hematopoietic function by inhibiting Bax translocation-mediated mitochondrial apoptosis in aplastic anemia. Sci Rep. 2021; 11(1):12742. PMC: 8211841. DOI: 10.1038/s41598-021-91471-1. View

17.

He J, Han R, Yu G, Lavin M, Jia Q, Cui P . Epimedium Polysaccharide Ameliorates Benzene-Induced Aplastic Anemia in Mice. Evid Based Complement Alternat Med. 2020; 2020:5637507. PMC: 7106868. DOI: 10.1155/2020/5637507. View

18.

Roderick J, Gonzalez-Perez G, Kuksin C, Dongre A, Roberts E, Srinivasan J . Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med. 2013; 210(7):1311-29. PMC: 3698520. DOI: 10.1084/jem.20112615. View

19.

Patel B, Townsley D, Scheinberg P . Immunosuppressive therapy in severe aplastic anemia. Semin Hematol. 2022; 59(1):21-29. DOI: 10.1053/j.seminhematol.2022.01.002. View

20.

Xiao Y, Zhao S, Li B . Aplastic anemia is related to alterations in T cell receptor signaling. Stem Cell Investig. 2017; 4:85. PMC: 5676186. DOI: 10.21037/sci.2017.09.07. View